miRcutis is the first biotechnology company to harness leading edge discoveries in gene expression to the consumer products sector. The Company is developing the first  generation of ribonucleic acid (RNA)-based biological active ingredients for use in the skincare market. The miRcutis technology platform RNA mediated phenotype modulation™ (RPM) is the connecting link between an individual’s genetic information, encoded in DNA, to its visual appearance, or phenotype. RPM targets three widespread skin conditions: impaired and aged skin, photoaging disorders, and pigmentation irregularities.

RNA has a unique ability to promote targeted phenotypes, a phenomenon which can occur naturally within the cell, but which miRcutis modulates through a class of small, non-protein coding RNA molecules called microRNA (miRNA). The discovery that the cell has precise mechanisms to control the expression of the genes in its genome, or “turning on or off” the instructions encoded in its DNA, was awarded the Nobel Prize in 2006.

Breakthrough RNA technology is being directed to innovations ranging from pharmacologics (cancer, Ebola), medical diagnostic tools (biomarkers), and high-performance crops (allergen-free peanuts, pesticide-free corn). For the first time, miRcutis now leads this breakthrough RNA science into the vast global markets for personal care products where consumers directly drive demand and influence product design.